Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?

Sean G. Kelly; Amesika N. Nyaku; Babafemi O Taiwo

doi:10.1007/s40265-016-0553-8

Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?

Sean G. Kelly, Amesika N. Nyaku, Babafemi O Taiwo^*

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

The advent of combination antiretroviral therapy (ART) has significantly decreased AIDS-related morbidity and mortality. Nevertheless, the benefits of ART are only realized through adherence to lifelong treatment. Though contemporary antiretroviral (ARV) drugs have fewer adverse effects in comparison to older ARV drugs, many agents are associated with negative or unknown long-term effects. There is increasing evidence that two-drug (dual-therapy) regimens may be an effective alternative to the currently recommended three-drug (triple-therapy) regimens. In this review, we provide a comprehensive and critical review of recently completed and ongoing trials of dual-therapy regimens in treatment-naïve and treatment-experienced HIV-1-infected patients. We also review current HIV/AIDS society recommendations regarding dual therapy as well as future therapeutic possibilities.

Original language	English (US)
Pages (from-to)	523-531
Number of pages	9
Journal	Drugs
Volume	76
Issue number	5
DOIs	https://doi.org/10.1007/s40265-016-0553-8
State	Published - Apr 2016

Funding

B. O. T. has served as a consultant for ViiV Healthcare, Gilead Sciences, Pfizer, and GlaxoSmithKline and received research support to Northwestern University from Pfizer. S. G. K and A. N. N declare no conflicts of interest.

ASJC Scopus subject areas

Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s40265-016-0553-8

Cite this

@article{47f269660ed24adca813ad711f26f5d5,

title = "Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?",

abstract = "The advent of combination antiretroviral therapy (ART) has significantly decreased AIDS-related morbidity and mortality. Nevertheless, the benefits of ART are only realized through adherence to lifelong treatment. Though contemporary antiretroviral (ARV) drugs have fewer adverse effects in comparison to older ARV drugs, many agents are associated with negative or unknown long-term effects. There is increasing evidence that two-drug (dual-therapy) regimens may be an effective alternative to the currently recommended three-drug (triple-therapy) regimens. In this review, we provide a comprehensive and critical review of recently completed and ongoing trials of dual-therapy regimens in treatment-na{\"i}ve and treatment-experienced HIV-1-infected patients. We also review current HIV/AIDS society recommendations regarding dual therapy as well as future therapeutic possibilities.",

author = "Kelly, {Sean G.} and Nyaku, {Amesika N.} and Taiwo, {Babafemi O}",

note = "Publisher Copyright: {\textcopyright} 2016 Springer International Publishing Switzerland.",

year = "2016",

month = apr,

doi = "10.1007/s40265-016-0553-8",

language = "English (US)",

volume = "76",

pages = "523--531",

journal = "Drugs",

issn = "0012-6667",

publisher = "Adis",

number = "5",

}

TY - JOUR

T1 - Two-Drug Treatment Approaches in HIV

T2 - Finally Getting Somewhere?

AU - Kelly, Sean G.

AU - Nyaku, Amesika N.

AU - Taiwo, Babafemi O

PY - 2016/4

Y1 - 2016/4

N2 - The advent of combination antiretroviral therapy (ART) has significantly decreased AIDS-related morbidity and mortality. Nevertheless, the benefits of ART are only realized through adherence to lifelong treatment. Though contemporary antiretroviral (ARV) drugs have fewer adverse effects in comparison to older ARV drugs, many agents are associated with negative or unknown long-term effects. There is increasing evidence that two-drug (dual-therapy) regimens may be an effective alternative to the currently recommended three-drug (triple-therapy) regimens. In this review, we provide a comprehensive and critical review of recently completed and ongoing trials of dual-therapy regimens in treatment-naïve and treatment-experienced HIV-1-infected patients. We also review current HIV/AIDS society recommendations regarding dual therapy as well as future therapeutic possibilities.

AB - The advent of combination antiretroviral therapy (ART) has significantly decreased AIDS-related morbidity and mortality. Nevertheless, the benefits of ART are only realized through adherence to lifelong treatment. Though contemporary antiretroviral (ARV) drugs have fewer adverse effects in comparison to older ARV drugs, many agents are associated with negative or unknown long-term effects. There is increasing evidence that two-drug (dual-therapy) regimens may be an effective alternative to the currently recommended three-drug (triple-therapy) regimens. In this review, we provide a comprehensive and critical review of recently completed and ongoing trials of dual-therapy regimens in treatment-naïve and treatment-experienced HIV-1-infected patients. We also review current HIV/AIDS society recommendations regarding dual therapy as well as future therapeutic possibilities.

UR - http://www.scopus.com/inward/record.url?scp=84958769130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958769130&partnerID=8YFLogxK

U2 - 10.1007/s40265-016-0553-8

DO - 10.1007/s40265-016-0553-8

M3 - Article

C2 - 26886135

AN - SCOPUS:84958769130

SN - 0012-6667

VL - 76

SP - 523

EP - 531

JO - Drugs

JF - Drugs

IS - 5

ER -

Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this